Epigenomics and nutrition

Forum of Nutrition

Volumn 60, Issue , 2007, Pages 31-41

  Cobiac, Lynne ^a,b  

^a CSIRO   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE;

ACETYLATION; CONFERENCE PAPER; DIET; DNA METHYLATION; GENETIC EPIGENESIS; HUMAN; METABOLISM; NUTRITION;

ACETYLATION; DIET; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; NUTRITION PHYSIOLOGY;

EID: 34547987198     PISSN: 16600347     EISSN: None     Source Type: Book Series    
DOI: 10.1159/0000107065     Document Type: Conference Paper

References (46)

1. Dietz AC, Zheng W, Leff MA, Gross WQ, Wen MA, Doll GH, Xiao GH, Folsom AR, Hein DW: N-acetyltransferase-2 genetic polymorphism, well-done meat intake and breast cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000;9:905-910.
2. Svetkey LP, Moore TJ, Simons-Morton DG, Appel LJ, Bray GA, Sacks FM, Ard JD, Mortensen RM, Mitchell SR, Conlin PR, Kesari M: Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study. J Hypertens 2001;19:1949-1956.
3. Simopoulos AP: Omega-6/Omega-3 essential fatty acid ratio and chronic diseases. Food Rev Int. 2004;20:77-90.
4. Yu W, Murray NR, Weems C, Chen L, Guo H, Ethridge R, Ceci JD, Evers BM, Thompson EA, Fields AP: Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis. J Biol Chem 2003;278:11167-11174.
5. Morris KV: siRNA-mediated transcriptional gene silencing: the potential mechanism and a possible role in the histone code. Cell Mol Life Sci 2005;62:3057-3066.
6. KondoY, Issa JP: Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 2004;23:29-39.
7. Johanning GL, Heimbergur DC, Piyathilake CJ: DNA methylation and diet in cancer. J Nutr 2002;132:3814S-3818S.
8. Fang MZ, Jin Z, Wang Y, Liao J, Yang GY, Wang LD, Yang CS: Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int. J Oncol 2005;26:615-622.
9. Raptis S, Bapat B: Genetic instability in human tumors. EXS 2006;96:303-320.
10. Davis CD, Ulthus EO: DNA methylation, cancer susceptibility, and nutrient interactions. Exp Biol Med (Maywood) 2004;229:988-995.
11. Abdolmalecky HM, Smith CL, Faraone SV, Shafa R, Stone W, Glatt SJ, Tsuang MT: Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet. B Neuropsychiatr Genet 2004; 127:51-59.
12. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S: S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005;28:195-204.
13. West RL, Lee JM, Maroun LE: Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J Mol Neurosci 1995;6:141-146.
14. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS: Tea polyphenol (-)epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563-7570.
15. Ferguson LR, Karunasinghe N, Philpott M: Epigenetic events and protection from colon cancer in New Zealand. Environ Mol Mutagen 2004;44:36:43.
16. Curtin K, Bigler J, Slattery ML, Caan B, Potter JD, Ulrich CM: MTHR C667T and A1298C polymorphisms: diet, estrogen and risk of colon cancer, Cancer Epidemiol Biomarkers Prev 2004;13:285-292.
17. Bailey LB: Folate methyl-related nutrients, alcohol and the MTHR 677C-T polymorphism affect cancer risk: intake recommendations. J Nutr 2003;133:3748S-3753S.
18. Pembrey ME, Bygren LO, Kaati G, et al: Sex-specific, male-line transgenerational responses in humans. Eur J Hum Genet 2006;14:159-166.
19. FU allele occurs following maternal and paternal transmission. Proc Natl Acad Sci USA 2003;100:2538-2543.
20. McMillen IC, Robinson JS: Developmental origins of the metabolic syndrome: prediction, plasticity and programming. Physiol Rev 2005;85:571-633.
21. Kelly TLJ, Trasler JM: Reproductive epigenetics. Clin Genet 2004;65:247-260.
22. Gallou-Kabani C, Junien C: Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetes 2005;54:1899-1906.
23. Cosgrove MS, Wolberger C: How does the histone code work? Biochem Cell Biol 2005;83:468-476.
24. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A: H2AX: the histone guardian of the genome. DNA Repair (Amst) 2004;3:959-967.
25. Fahrner JA, Eguchi S, Herman JG, Baylin SB: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002;62:7213-7218.
26. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta T, et al: Loss of acetylation at Lysl 6 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
27. Acharya MR, Sparreboom A, Venitz J, Figg WD: Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005;68:917-932.
28. Mattson MP: Methylation and acetylation in nervous system development and neurodegenerative disorders. Ageing Res Rev 2003;2:329-342.
29. Simoni MV, Camargo LM, Dong E, Maloku E, Veldic M, Costa E, Guidotti A: The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006;103:1587-1592.
30. Gray ST, DeMeyts P: Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab Res Rev 2005;21:416-433.
31. Dashwood RH, Myzak MC, Ho E: Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 2006;27:344-349.
32. Fenech M: The Genome Health Clinic and genome health nutrigenomics concepts: diagnosis and nutritional treatment of genome and epigenome damage on an individual basis. Mutagenesis 2005;20:255-269.
33. Bonassi S, Hagmar L, Stromberg U, et al: Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. Cancer Res 2000;60:1619-1625.
34. Migliore L, Botto N, Scarpato R, Petrozzi L, Cipriani G, Bonuccelli U: Preferential occurrence of chromosome 21 malsegregation in peripheral blood lymphocytes of Alzheimer's disease patients. Cytogenet Cell Genet 1999;87:41-46.
35. Migliore L, Scarpato R, Coppede F, Petrozzi L, Bonucelli U, Rodilla V: Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients. Int J Hyg Environ Health 2001;204:61-66.
36. Mathers JC: The biological evolution - towards a mechanistic understanding of the impact of diet on cancer risk. Mutat Res 2004;5 51:43-49.
37. Reddy L, Odhav B, Bhoola KD: Natural products for cancer prevention: a global perspective. Pharmacol Ther 2003;99:1-13.
38. Schneider Y, Vincent F, Duranton B, Badolo L, Gosse F, Bergmann C, Seiler N, Raul F: Antiproliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 2000;158:85-91.
39. Augenlicht LH, Mariadason JM, Wilson A, Arango D, Yang W, Heerdt BG, Velcich A: Short chain fatty acids and colon cancer. J Nutr 2002;132:3804S- 3808S.
40. Ng Y, Barhoumi R, Tjalkens RB, Fan YY, Kolar S, Wang NY, Lupton JT, Chapkin RS: The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis 2005;26:1914-1921.
41. Augustin MA, Sanguansri L, Bode O: Maillard reaction products as encapsulants for fish oil pow-ders. J Food Sci 2006;71:E25-E32.
42. Annison G, Illman RJ, Topping DL: Acetylated, proprionylated and butyrylated starches raise large bowel short-chain fatty acids preferentially when fed to rats. J Nutr 2003;133:3523-3528.
43. Chadwick R: Nutrigenomics, individualism and public health. Proc Nutr Soc 2004;63:161-166.
44. Fenech M: Recommended, dietary allowances (RDAs) for genomic stability. Mutat Res 2001;480:51-54.
45. Moskaug JO, Carlsen H, Myhrstad M, Blomhoff R: Molecular imaging of the biological effects of quercetin and quercetin-rich foods. Mech Ageing Dev 2004; 125:315-324.
46. Wynter CV: The dialectics of cancer: a theory of the initiation and development of cancer through errors in RNAi. Med Hypotheses 2006;66:612-635.